Evidence map›Paper›PMID 31330185›Full record

ReviewSeminars in cancer biology2020

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Shaheen Khan, David E Gerber

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cancer biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 8 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 8 syntheses or guidelines pooled it, 249 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shaheen KhanDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9093, United States. Electronic address: Shaheen.khan@utsouthwestern.edu.
David E GerberDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9093, United States; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9093, United States; Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9093, United States. Electronic address: David.Gerber@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · US

Funding

Development of New Cancer Treatments and InvestigatorsK24CA201543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERBER, DAVID ERIC · 2016 to 2020
$737k
NCI NIH HHS K24 CA201543
6 · The paper itself

Abstract

Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse cancer types. However, a significant number of patients on checkpoint inhibitors develop immune-related adverse events (irAEs) affecting a wide variety of organs. These events, which may reflect enhanced T cell activation, are unpredictable, heterogeneous, and in some instances permanent or life-threatening. It is not clear whether these toxicities are distinct from conventional autoimmune diseases or whether the manifestation of irAEs is associated with therapeutic efficacy. Studies across the spectrum of basic, preclinical and clinical research deciphering the role of genetics, epigenetics, gut microbiota and underlying immune status of patients who develop irAEs are required to gain a deeper mechanistic understanding. Insights gained from such studies will facilitate identification of biomarkers for optimal treatment and clinical management of patients. In this Review, we provide basic and clinical understanding of immune checkpoint inhibitors and irAEs. We discuss the connection between immune system, autoimmunity and cancer; immune checkpoint inhibitors and associated autoimmune toxicities; insights into potential underlying mechanisms of irAEs; impact of autoimmune diagnosis on cancer outcome; and management of irAEs.

Indexed as

AnimalsAutoimmune DiseasesAutoimmunityBiomarkers, TumorHumansImmunologic FactorsImmunotherapyNeoplasmsBiomarkers, TumorImmunologic FactorsAutoimmunityImmune checkpoint inhibitorsImmunotherapyToxicity and irAEs

Identifiers

PMID31330185
PMCPMC6980444
OpenAlexW2963849817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.